Innovo Mimetics

Company Overview

Snapshot

Founded in March 2010 by Jonathan Goldstein, Innovo Mimetics operates with 1–10 employees. The company has raised $160K across 4 funding rounds. Innovo Mimetics ceased operations in December 2024.

Business overview

Innovo Mimetics specializes in developing anti-cancer therapy efficacy assays using a proprietary chick egg tumor xenograft model. Their core product, ScreenOvo, is a service tool designed for immunotherapy and pharmaceutical companies to rapidly and cost-effectively evaluate chemical, biological, and cell therapies. This system provides xenograft tumor data to expand cancer therapy pipelines, generate proofs of concept, screen for lead products, and reduce research risks before investing in more intensive mouse models. Innovo Mimetics operates within the Health Tech & Life Sciences sector, focusing on drug discovery and development for oncology, immunology, and personalized medicine.

Company Intelligence Q&A

What is Innovo Mimetics' primary focus?

Innovo Mimetics specializes in anti-cancer therapy efficacy assays using a proprietary chick egg tumor xenograft model.

When was Innovo Mimetics founded?

Innovo Mimetics was founded in March 2010.

Who founded Innovo Mimetics?

Jonathan Goldstein is the founder and CEO of Innovo Mimetics.

What is the status of Innovo Mimetics?

Innovo Mimetics is non-active and ceased to operate in December 2024.

What is ScreenOvo?

ScreenOvo is Innovo Mimetics' proprietary assay system that allows rapid and low-cost evaluation of chemical, biological, and cell therapies using a living tumor in a chick egg model.